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Abstract
Background: Visceral fat area (VFA), a novel sex-specific index for visceral fat obesity (VFO) might play a major role
in the development of vitamin D deficiency. However, the association between VFA and vitamin D insufficiency and
deficiency in Chinese population is less clear. The aim of this study was to explore the population-level association
between VFA and vitamin D insufficiency and deficiency among Chinese men and women.
Methods: This cross-sectional study involved 1105 adults aged 20–70 years living in Tianjin who were randomly selected
and medically examined. All subjects underwent the bioelectrical impedance analysis (BIA) method to estimate the VFA.
Serum 25-hydroxyvitamin D3 (25(OH) D3) level was assayed by the high-performance liquid chromatography (HPLC)
method and defined insufficiency and deficiency following recommended cutoffs. The association between VFA and
vitamin D insufficiency and deficiency was estimated using binary regression analysis.
Results: The total prevalence of vitamin D insufficiency (25(OH) D3: 20–29 μg/L) and deficiency (25(OH) D3 < 20 μg/L)
were 26.60 % and 24.89 %, respectively. Significant negative association was observed for VFA with serum 25(OH) D3
levels in men and pre-menopausal women (P < 0.05), not in post-menopausal women (P > 0.05). Moreover, increased
VFA was observed to be associated with higher vitamin D insufficiency or deficiency risk with a positive dose–response
trend (P for trend < 0.001). As compared to individuals with the lowest VFA, those who had the highest VFA were at
4.9-fold risk of vitamin D insufficiency and deficiency [95 % confidence interval (95 % CI): 1.792–13.365] in men and
1.8-fold risk of vitamin D insufficiency and deficiency (95 % CI: 1.051–3.210) in pre-menopausal women, but not in
post-menopausal women [odds ratio (OR) (95 % CI): 2.326(0.903–5.991)].
Conclusions: These results suggest that higher VFA increases the risk of vitamin D insufficiency and deficiency in men
and pre-menopausal women, but not in post-menopausal women. VFA is a better and convenience surrogate marker
for visceral adipose measurement and could be used in identifying the risk of vitamin D insufficiency and deficiency in
routine health examination.
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Background
Vitamin D deficiency is now being recognized as a major
global public health problem [1–3]. Approximately 1
billion people worldwide have vitamin D deficiency [4]. In
China, vitamin D deficiency is common in the middle-
aged and elderly population. The prevalence of vitamin D
deficiency was 69.2 % in Beijing and Shanghai [5], and the
prevalence of vitamin D deficiency was 75.2 % in the
northwestern inland of China [6].
Traditional roles of vitamin D lie within the musculo-
skeletal system, maintaining calcium homoeostasis and
bone metabolism. In recent years, new functional roles of
vitamin D have emerged linking the fat-soluble vitamin to
various non-communicable diseases. The consequences of
vitamin D deficiency include poor bone development and
health as well as increase risk of many chronic diseases
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including insulin resistance, diabetes and cardiovascular
disease [7], which is also commonly linked with obesity
and visceral fat obesity (VFO).
Anthropometric indices such as body mass index
(BMI) have been used widely in the previous studies
examining the relationship between obesity and vitamin
D [8, 9]. In particular, VFO compared with overall obes-
ity might play a major role in the development of vita-
min D deficiency. Therefore, estimating visceral fat
accumulation is important to identify individuals at high
risk for vitamin D deficiency. Their inability to distin-
guish visceral fat precludes their ability to accurately
assess abdominal fat accumulation. Because fat accumu-
lation in different areas represents different risk for
metabolic disorders and visceral adipose tissue may be
unique [10], we sought to evaluate visceral fat. Conven-
tionally, the simplest and most widely used method of
assessing visceral fat accumulation is measuring the
waist circumference (WC) [11]. Although WC is recog-
nized as an independent and powerful risk factor for
vitamin D deficiency, there might be substantial varia-
tions in the visceral fat amount among persons with a
similar WC because WC itself performs poorly in dis-
criminating between visceral and subcutaneous fat.
Therefore, it is possible that subjects with a normal WC
may be more prone to vitamin D deficiency if they have
centrally located body fat. Many sophisticated methods
such as dual-energy x-ray absorptiometry (DEXA), com-
puted tomography (CT) and magnetic resonance im-
aging (MRI) have been developed to provide more
precise estimates of the location and amount of adipose
tissue in various body regions [12]. However, DEXA, CT
and MRI are impractical for screening general population,
since they require expensive and specialized equipment,
and exposure to radiation. Studies have compared the
general usage of bioelectrical impedance analysis (BIA)
with one of these more established methods (CT, MRI or
DEXA). BIA has been shown to accurately predict DXEA-
derived percentage body fat (PBF) in the Chinese popula-
tion (r = 0.89, P < 0.05) [13]. VFA measured by BIA corre-
lated significantly with that acquired by CT (r = 0.992 for
VFA, using data from the Biospace of 332 patients) [14].
Although BIA is not considered a “gold standard”, BIA
has been considered a valid alternative for measuring body
fat in large studies or clinical practice [15], which has also
been validated against reference methods [13, 14].
Visceral fat area (VFA), a novel sex-specific index for
VFO, has been proposed recently. One study has exam-
ined the association of 25-hydroxyvitamin D3 (25(OH)
D3) level and VFO in Chinese men and discovered serum
25(OH)D3 levels were inversely associated with VFA [16].
To our knowledge, serum 25(OH) D3 levels and the distri-
bution of abdominal fat are known to be distinctive
between men and women [17–19], as well as between
pre-memopausal and post-memopausal women. However,
the significance of association between VFA and vitamin
D insufficiency and deficiency in the Chinese population
is less clear. In the present study, a simple method for the
measurement of visceral fat accumulation using BIA [20]
was performed to explore the population-level association
between VFA and vitamin D insufficiency and deficiency
in Chinese men and women.
Methods
Subjects
This overall population includes 1130 subjects aged 20–
70 years coming to the Health Examination Center of
Heping District in Tianjin, China for routine health
checkup during November to December in 2013, were
enrolled. 1105 subjects were included for analysis ac-
cording to the following inclusion and exclusion criteria.
Inclusion criteria were as follows: 1) aged 20–70 years,
2) written informed consent, 3) willingness to take part
in the examination and willingness to provide blood
samples. Exclusion criteria were as follows: 1) individuals
whose medical data were incomplete (n = 10), 2) individ-
uals who took diuretics (n = 3), 3) individuals who
undergone hormone replacement therapy (n = 2), 4) in-
dividuals with chronic kidney disease (n = 3), 5) individ-
uals with presence of tumor, infectious diseases or
psychiatric disease (n = 3), 6) individuals with severe dis-
ability or occurrence of bone fracture within the past six
months (n = 2); 7) individuals who have had stents or
with history of cardiovascular disease (n = 2).
The study was conducted in accordance with the
Declaration of Helsinki and approved by the Ethics
Committee of Tianjin Medical University. All study
participants provided written informed consent prior
to enrollment.
Body fat measurements
Body fat measurements, consisting of BMI, WC,
waist-to-hip ratio (WHR), fat mass (FM), free fat
mass (FFM), PBF and VFA were estimated by the BIA
method (Inbody 720 Body Composition Analyzer,
Korean).
Anthropometric and biochemical assessments
Systolic blood pressure (SBP) and diastolic blood pressure
(DBP) were measured by trained nurses with a mercury
sphygmomanometer on the right arm of the subjects in a
comfortable siting position after 5 -min rest. After 10-h
overnight fasting, blood samples were collected from all
subjects to measure serum 25(OH) D3 levels as well as
other biochemical parameters. Fasting plasma glucose
(FPG) was measured by the glucose oxidase method. Lipid
profiles, including total cholesterol (TC) and triglycerides
(TG) were determined using the standard enzymatic
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methods, while low-density lipoprotein cholesterol (LDL-c)
and high-density lipoprotein cholesterol (HDL-c) were
determined by the direct assay method. All of the above
measurements were carried out on a Hitachi 7600–120
auto-analyzer (Tokyo, Japan). Total serum 25(OH) D3 level
was assayed by the high-performance liquid chromatog-
raphy (HPLC) method.
Definition of terms
Obesity was defined as a BMI value exceeding 28 kg/m2
[21]. VFO was defined as WC ≥ 90 cm for men or ≥80 cm
for women. Or VFO was defined as a VFA exceeding
130 cm2 in men and 100 cm2 in women [22]. Vitamin D
status was defined as follows: A serum level of 25(OH)
D3 < 20 μg/L is considered to be vitamin D deficiency,
whereas a level 20–29 μg/L is insufficient, and to
maximize vitamin D’s effect for health, 25(OH) D3
should be ≥30 μg/L [23].
Lifestyle factors
Smoking behavior, drinking behavior, current daily time
spent outdoors, physical activity, menopausal status
and vitamin D supplement intake were collected using
self-administered questionnaires. The current time
spent outdoors (h/d) was used as an indicator for sun-
shine time. A woman was considered post-menopausal
if she reported menses had ceased for 1 year or more,
and age at menopause was self-reported as previously
reported.
Statistical analysis
According to the sample size, a normal distribution was
tested by the Kolmogorov-Smirnov test with the Lilliefors
correction for men and women. Normally distributed vari-
ables were presented as the mean ± standard deviation,
whereas skewed variables were presented as the median
(interquartile range). Because of significant sex difference
in the amount of total body fat, fat distribution and life-
style factors, we performed sex-stratified analyses. For
continuous variables, the independent sample t-test and
the Wilcoxon rank-sum test were used for between-group
comparisons of normally distributed and skewed data, re-
spectively. Comparative analyses of categorical variables
were carried out using a Chi-square test. Each participant
was categorized into one of four subgroups depending on
their total VFA. To compare variables between these sub-
groups, one-way analysis of variance (ANOVA) followed
by Scheffé post hoc test or Mann–Whitney U test were
used where appropriate. Partial correlation analyses be-
tween serum 25(OH) D3 and other variables were adjusted
for age. Binary logistic regression was performed to exam-
ine the association between body fatness indices and vita-
min D insufficiency and deficiency. Data were analyzed
using SPSS (Chicago, IL) version 13.0 statistical software.
P value less than 0.05 was considered to indicate a statisti-
cally significant difference.
Results
Descriptive characteristics of the study population
The characteristics of the study population were shown in
Table 1. Overall, the prevalence of visceral fat obesity was
higher than obesity. It was showed that the men had a
higher age, WHR, BMI, WC, FM, VFA, FFM, SBP, DBP,
sunshine time, higher levels of TG, LDL-c, FPG and lower
levels of PBF, 25(OH) D3 and HDL-c. But there was no
difference in TC and vitamin D supplementation intake
between the men and women. The prevalence of obesity,
visceral fat obesity and vitamin D deficiency in men was
higher than in the women, whereas the prevalence of vita-
min D insufficiency in men was lower than in the women.
Characteristics of the study population according to the
quartiles of VFA
The study subjects were also divided into four groups ac-
cording to the quartiles of VFA in men and women. The
analysis revealed a increasing trend in VFA that accom-
panied increases in BMI, WC, WHR, FM, FFM, PBF and
TG in both genders, decreases in 25(OH)D3 in men and
pre-menopausal women (Table 2, Table 3). Intergroup
comparisons revealed that the Q2, Q3 and Q4 groups had
significantly lower 25(OH) D3 than the Q1 group in men
(Table 2), whereas the Q4 groups had significantly lower
25(OH) D3 than the Q2 group and Q1 group in pre-
menopausal women (Table 3).
Prevalence of vitamin D insufficiency and vitamin D
deficiency according to the quartiles of VFA
Figure 1a showed that the prevalence of vitamin D defi-
ciency increased in men and in pre-menopausal women
according to the quartiles of VFA (P <0.05), but not in
post-menopausal women (P >0.05). The prevalence of
vitamin D deficiency in the fourth quartile of VFA in
men (46.88 %) and in pre-menopausal women (28.10 %)
were significantly higher than that in the first quartile
(15.63 % in men and 13.07 % in pre-menopausal
women), second quartile (35.38 % in men and 16.67 % in
pre-menopausal women) and third quartile (35.94 % in
men and 17.18 % in pre-menopausal women) (P <0.05)
(Fig. 1a). Increased VFA was observed to be associated
with higher vitamin D deficiency risk with a positive
dose–response trend in men and pre-menopausal
women (P for trend < 0.001), not in post-menopausal
women. The prevalence of vitamin D insufficiency in the
fourth quartile of VFA in men (28.13 %) was significantly
higher than that in the first quartile (9.23 %) and second
quartile (12.50 %) (Fig. 1b). However, the prevalence of
vitamin D insufficiency did not increase with the
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quartiles of VFA in pre-menopausal women and post-
menopausal women (P >0.05) (Fig. 1b).
Relationship between VFA and vitamin D insufficiency
and deficiency
Partial correlation analysis showed that serum 25(OH) D3
levels were negatively correlated with VFA and other body
fatness indices in men (Fig. 2a-e) and pre-menopausal
women (Fig. 2f-j) (all P < 0.05), not in post-menopausal
women (Fig. 2k-o). We also assessed the odds ratios (ORs)
and 95 % confidence intervals (CIs) of VFA levels and vita-
min D insufficiency and deficiency. After adjusting for age,
smoking status, drinking status, exercise status, sun exposure
and lipid profiles, as compared to individuals with the lowest
VFA, those who had the highest VFA were at 4.9-fold risk of
vitamin D insufficiency and deficiency (95 % CI: 1.792–
13.365) in men and 1.8-fold risk of vitamin D insufficiency
and deficiency (95 % CI: 1.051–3.210) in pre-menopausal
women, not in post-menopausal women (Table 4).
Discussion
In this cross-sectional study, we confirmed that visceral
fat obesity was an important risk factor of vitamin D
Table 1 Descriptive characteristics of the study population
Characteristics Total Men Women P-valuea
n 1105 257 848
Age, y 43.82 ± 12.15 45.44 ± 12.18 43.33 ± 12.11 0.015
Body mass index, kg/m2 23.67 ± 3.37 26.18 ± 3.39 22.90 ± 2.97 <0.001
Waist circumference, cm 82.79 ± 9.08 90.42 ± 8.57 80.48 ± 7.90 <0.001
Waist-to- hip ratio 0.87 ± 0.05 0.91 ± 0.04 0.84 ± 0.04 <0.001
Fat mass, kg 20.13 ± 6.06 21.45 ± 6.91 19.73 ± 5.72 <0.001
Free fat mass, kg 44.66 ± 8.96 58.41 ± 6.56 40.50 ± 4.11 <0.001
Percentage body fat, % 30.89 ± 6.06 26.35 ± 5.57 32.27 ± 5.51 <0.001
Visceral fat area, cm2 87.30 ± 35.44 116.13 ± 34.87 78.56 ± 30.68 <0.001
Systolic blood pressure, mmHg 113.79 ± 15.72 120.54 ± 12.72 111.07 ± 16.01 <0.001
Diastolic blood pressure, mmHg 75.52 ± 10.06 80.30 ± 9.34 73.59 ± 9.70 <0.001
Total cholesterol, mmol/L 4.98 ± 0.98 5.03 ± 0.95 4.97 ± 1.00 bNS
Triglycerides, mmol/L 1.03(0.73–1.51) 1.41(0.99–2.00) 0.95(0.69–1.36) <0.001
High-density lipoprotein cholesterol, mmol/L 1.33 ± 0.28 1.16 ± 0.21 1.38 ± 0.28 <0.001
Low-density lipoprotein cholesterol, mmol/L 2.96 ± 0.80 3.10 ± 0.76 2.92 ± 0.82 0.001
Fasting plasma glucose, mmol/L 5.73 ± 1.03 5.96 ± 1.28 5.66 ± 0.92 <0.001
25(OH)D3, μg/L 36.46 ± 24.70 33.26 ± 19.80 37.44 ± 25.94 0.018
Smoking, % yes 11.86 42.80 2.48 <0.001
Drinking, % yes 38.82 70.04 29.36 <0.001
Doing exercise, % yes 46.06 64.98 40.33 <0.001
Sunshine time, h/day 0.5(0.0,1.0) 1.0(0.0,2.0) 0.5(0.0,1.0) <0.001
Vitamin D supplement users, % yes 2.26 2.33 2.24 bNS
Obesity, % 13.76 29.18 9.08 <0.001
Visceral fat obesity, %
Men: WC ≥90 cm; women: WC≥ 80 cm 44.71 50.58 42.92 0.031
Men: VFA ≥130 cm2; women: VFA≥ 100 cm2 23.53 35.40 19.92 <0.001
25(OH)D3 status
*
Vitamin D insufficiency, % 26.60 18.68 29.00 0.001
Vitamin D deficiency, % 24.89 33.46 22.29 <0.001
Values are percentages for categorical variables, means ± SDs for continuous variables with a normal distribution, or medians (95 % ranges) for continuous
variables with a skewed distribution
Abbreviations: WC, waist circumference; VFA, visceral fat area; 25(OH)D3, 25-hydroxyvitamin D
aComparison among men and women
bNS = no significant at p value > .05
*25(OH)D3 status was defined as follows: A serum level of 25(OH) D3 < 20 μg/L is considered to be vitamin D deficiency, whereas a level 20–29 μg/L is insufficient
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insufficiency and deficiency among Chinese men and pre-
menopausal women, and discovered the increase of
visceral adiposity was positively associated with vitamin D
insufficiency or deficiency risk with clear dose–response
relationship.
There is evidence that vitamin D metabolism, storage,
and action both influence and are influenced by adiposity.
Observational studies have reported that an increased risk
of vitamin D deficiency in those people with obesity [24].
Active vitamin D (1, 25-dihydroxyvitamin D) may influ-
ence the mobilisation of free fatty acids from the adipose
tissue [25]. In vitro experiments in rats have also shown
that large doses of vitamin D2 lead to increases in energy
expenditure due to uncoupling of oxidative phosphoryl-
ation in adipose tissues [26]. Consistent with the experi-
mental studies, our result has indicated that serum
25(OH) D3 levels decreased significantly in subjects with
visceral obesity and has shown that this decrease was
closely correlated with fat distribution [27, 28].
Although the mechanism for the association between
obesity and vitamin D insufficiency is not well understood,
researches suggested that individuals with obesity were
prone to vitamin D insufficiency [29–31], possibly as the
result of increased sequestration of vitamin D in the
increased amounts of visceral adipose tissue in individuals
with obesity [30]. This may lead to less vitamin D released
into the blood, and consequently these individuals may
have lower serum 25(OH) D3 levels. Such individuals may
therefore need to increase their vitamin D intake to attain
serum 25(OH) D3 levels comparable with individuals with
normal BMI [29]. Evidence also suggests that vitamin D in-
sufficiency may stimulate lipogenesis as the result of
increased calcium influx into the adipocytes mediated by
increased synthesis of parathyroid hormones [32]. This
would suggest that vitamin D insufficiency could cause
obesity. Minimal outdoor activity and maximum skin cov-
ering by clothing among the population with obesity also
limits photochemical subcutaneous synthesis of vitamin D
Table 2 Characteristics of the study population according to quartiles of visceral fat area levels in men
Quartiles of visceral fat area (cm2) P-valuea
Q1 (<89.95) Q2 (89.95–115.72) Q3 (115.72–140.46) Q4 (≥140.46)
n 64 65 64 64
Age, y 42.36 ± 12.69 45.29 ± 12.03 46.92 ± 12.06 47.17 ± 11.58 bNS
Body mass index, kg/m2 22.87 ± 2.23 25.59 ± 2.21# 26.80 ± 2.51#& 29.45 ± 2.77#&$ 0.000
Waist circumference, cm 81.28 ± 5.58 88.36 ± 4.93# 92.48 ± 5.50#& 99.57 ± 5.83#&$ 0.000
Waist-to-hip ratio 0.86 ± 0.03 0.90 ± 0.02# 0.92 ± 0.02#& 0.95 ± 0.02#&$ 0.000
Fat mass, kg 14.08 ± 3.52 19.90 ± 3.67# 23.35 ± 4.97#& 28.51 ± 5.64#&$ 0.000
Free fat mass, kg 55.38 ± 6.43 57.40 ± 6.06# 58.17 ± 5.60#& 62.75 ± 5.93#&$ 0.000
Percentage body fat, % 20.14 ± 3.63 25.68 ± 3.39# 28.50 ± 4.28#& 31.08 ± 4.02#&$ 0.000
Systolic blood pressure, mmHg 118.89 ± 11.35 121.78 ± 12.12 118.41 ± 11.35 122.93 ± 14.70 bNS
Diastolic blood pressure, mmHg 78.19 ± 7.57 80.22 ± 10.05 80.57 ± 8.16 81.95 ± 10.95 bNS
Total cholesterol, mmol/L 4.71 ± 0.78 4.93 ± 1.08 5.17 ± 0.90# 5.31 ± 0.90#& 0.001
Triglycerides, mmol/L 0.99(0.72–1.46) 1.38(0.94–2.10)# 1.53(1.22–2.11)# 1.69(1.26–2.18)# 0.036
High-density lipoprotein cholesterol, mmol/L 1.22 ± 0.23 1.14 ± 0.21 1.13 ± 0.21 1.15 ± 0.18 bNS
Low-density lipoprotein cholesterol, mmol/L 2.85 ± 0.66 2.91 ± 0.68 3.24 ± 0.76#& 3.44 ± 0.79#& 0.000
Fasting plasma glucose, mmol/L 5.63 ± 0.95 6.10 ± 1.36 5.99 ± 1.13 6.13 ± 1.58 bNS
25(OH)D3, μg/L 42.30 ± 19.59 34.90 ± 20.93
# 30.80 ± 20.15# 25.01 ± 14.05#& 0.000
Smoking, % yes 28.13 41.54# 43.75# 57.81# 0.009
Drinking, % yes 57.81 73.85 71.88 76.56 bNS
Doing exercise, % yes 51.56 67.69 67.19 73.44 bNS
Sunshine time, h/day 1.00(0.50–1.00) 1.00(0.00–3.00) 0.50(0.00–1.50) 1.00(0.00–2.00) bNS
Vitamin D supplement users, % yes 1.56 0.00 6.25 1.56 bNS
Values are percentages for categorical variables, means ± SDs for continuous variables with a normal distribution, or medians (95 % ranges) for continuous
variables with a skewed distribution
Abbreviations: 25(OH) D3, 25–hydroxyvitamin D3
aComparison among four groups
bNS = no significant at p value > .05
#Compared with Q1, P < 0.05
&Compared with Q2, P < 0.05
$Compared with Q3, P < 0.05
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Table 3 Characteristics of the study population according to quartiles of visceral fat area levels in women
Pre-menopausal women
Quartiles of visceral fat area (cm2) P-valuea
Q1 (<53.15) Q2 (53.15–66.18) Q3 (66.18–84.47) Q4 (≥84.47)
n 153 144 163 153
Age, y 33.09 ± 6.30 36.54 ± 7.54# 38.35 ± 6.91#& 41.27 ± 7.41#&$ 0.000
Body mass index, kg/m2 20.51 ± 1.33 21.54 ± 1.46# 22.44 ± 1.77#& 25.48 ± 3.46#&$ 0.000
Waist circumference, cm 73.06 ± 3.74 76.67 ± 3.48# 79.62 ± 3.92#& 88.27 ± 7.90#&$ 0.000
Waist-to-hip ratio 0.81 ± 0.02 0.84 ± 0.02# 0.86 ± 0.02#& 0.90 ± 0.04#&$ 0.000
Fat mass, kg 14.39 ± 2.71 17.02 ± 2.90# 18.99 ± 3.08#& 24.93 ± 5.80#&$ 0.000
Free fat mass, kg 39.65 ± 3.46 39.84 ± 3.69 40.16 ± 3.42 43.23 ± 4.85#&$ 0.000
Percentage body fat, % 26.53 ± 3.69 29.85 ± 3.74# 32.01 ± 3.58#& 36.26 ± 4.46#&$ 0.000
Systolic blood pressure, mmHg 102.64 ± 12.01 102.31 ± 10.81 106.97 ± 112.46# 110.85 ± 15.45#& 0.000
Diastolic blood pressure, mmHg 69.03 ± 8.46 69.18 ± 7.37 72.13 ± 8.73 74.38 ± 10.18#& 0.001
Total cholesterol, mmol/L 4.42 ± 0.72 4.63 ± 0.77# 4.73 ± 0.87# 4.90 ± 0.87#&$ 0.000
Triglycerides, mmol/L 0.66(0.58–0.86) 0.79(0.64–1.07)# 0.94(0.69–1.25)#& 1.16(0.80–1.55)#&$ 0.000
High-density lipoprotein cholesterol, mmol/L 1.46 ± 0.29 1.41 ± 0.30 1.32 ± 0.24#& 1.26 ± 0.25#& 0.000
Low-density lipoprotein cholesterol, mmol/L 2.41 ± 0.62 2.64 ± 0.63# 2.81 ± 0.76#& 3.02 ± 0.75#&$ 0.000
Fasting plasma glucose, mmol/L 5.29 ± 0.47 5.37 ± 0.45 5.55 ± 0.78#& 5.77 ± 0.90#&$ 0.000
25(OH)D3, μg/L 43.25 ± 28.90 42.30 ± 28.02 38.39 ± 24.11 35.80 ± 27.38#& 0.002
Smoking, % yes 0.65 0.69 0.61 0.65 bNS
Drinking, % yes 22.22 25.00 24.54 29.41 bNS
Doing exercise, % yes 44.44 48.61 43.56 47.06 bNS
Sunshine time, h/day 1.00(0.50–0.10) 1.00(0.00–1.00) 1.00(0.50–0.10) 1.00(0.50–0.10) bNS
Vitamin D supplement users, % yes 1.96 0.69 1.23 0.65 bNS
Post-menopausal women
Quartiles of visceral fat area (cm2) P-valuea
Q1(<71.55) Q2(71.55–91.97) Q3(91.97–115.73) Q4(≥115.73)
n 59 59 59 58
Age, y 58.17 ± 7.74 59.25 ± 5.49 58.95 ± 5.60 59.38 ± 5.81 bNS
Body mass index, kg/m2 21.43 ± 1.60 22.62 ± 1.22# 24.18 ± 2.00#& 27.64 ± 2.51#&$ 0.000
Waist circumference, cm 75.57 ± 4.19 79.47 ± 2.73# 84.24 ± 4.41#& 93.64 ± 6.10#&$ 0.000
Waist-to-hip ratio 0.82 ± 0.02 0.86 ± 0.01# 0.89 ± 0.01#& 0.93 ± 0.03#&$ 0.000
Fat mass, kg 16.80 ± 2.85 19.42 ± 2.35# 22.66 ± 3.51#& 29.18 ± 4.87#&$ 0.000
Free fat mass, kg 38.72 ± 3.89 38.79 ± 2.88 39.66 ± 3.24 42.51 ± 4.45#&$ 0.000
Percentage body fat, % 30.18 ± 3.77 33.34 ± 3.03# 36.25 ± 3.45#& 40.55 ± 3.97#&$ 0.000
Systolic blood pressure, mmHg 115.14 ± 14.90 120.78 ± 18.67 122.36 ± 13.65 124.88 ± 15.37 bNS
Diastolic blood pressure, mmHg 75.97 ± 9.47 76.72 ± 8.67 77.22 ± 8.23 81.63 ± 10.04#&$ 0.029
Total cholesterol, mmol/L 5.64 ± 0.93 5.84 ± 0.10 5.88 ± 1.17 5.58 ± 0.82 bNS
Triglycerides, mmol/L 1.10(0.67–1.40) 1.21 (0.93–1.50)# 1.40(1.07–1.94)#& 158(1.16–1.89)#& 0.000
High-density lipoprotein cholesterol, mmol/L 1.55 ± 0.30 1.42 ± 0.23# 1.33 ± 0.25# 1.35 ± 0.26# 0.000
Low-density lipoprotein cholesterol, mmol/L 3.31 ± 0.80 3.57 ± 0.73 3.54 ± 0.85 3.33 ± 0.81 bNS
Fasting plasma glucose, mmol/L 5.75 ± 1.34 6.06 ± 1.13 6.35 ± 1.51 6.10 ± 0.84 bNS
25(OH)D3, μg/L 33.04 ± 22.62 33.63 ± 20.89 29.77 ± 20.90 27.78 ± 19.64 bNS
Smoking, % yes 3.39 6.78 8.47 10.34 bNS
Drinking, % yes 33.90 38.98 40.68 46.55 bNS
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[31]. Although we have found an association between VFA
and vitamin D insufficiency and deficiency, we used cross-
sectional data, and thus, were precluded from establishing
a temporal relationship between VFA and vitamin D
insufficiency and deficiency. However, clinical trials have
failed to conclusively demonstrate the benefits of vitamin
D supplementation. Randomized controlled trials testing
the effect of vitamin D supplementation on weight loss in
individuals with obesity or overweight have provided in-
consistent findings [33–35]. Dilution related to the greater
volume of distribution has been recently proposed as the
most likely explanation for the lower 25(OH) D3 concen-
trations in individuals with obesity [36]. In that study, no
evidence was found for reduced bioavailability through in-
creased sequestration of vitamin D in the adipose tissue,
which had previously been suggested to contribute to the
low 25(OH) D3 concentrations in obesity. Therefore, these
results suggested that although increased in vitamin D sta-
tus were not likely to help with weight regulation, in-
creased risk of vitamin D deficiency could contribute to
the adverse health effects associated with obesity. Recent
study has showed that higher BMI led to lower vitamin D
status, providing evidence for the role of obesity as a causal
risk factor for the development of vitamin D deficiency on
the basis of a bi-directional genetic approach [37].
Next to common adiposity measures, we also discovered
that VFA was inversely associated with serum 25(OH) D3
concentrations in Chinese men and pre-menopausal
women, which was similar to the recent study in Northeast
Germany and Denmark [38] and China [16]. Differed from
Hao’s study among Chinese population, our study popula-
tion included men and women, and included the partici-
pants who were diabetes. Especially, we have observed that
the men had the higher risk for vitamin D insufficiency and
deficiency. It was because the prevalence of obesity and
visceral obesity in men was higher than in women. Obesity
is known to be associated with decreased bioavailability of
vitamin D, which is sequestered in body fat [30]. Moreover,
there was a clear difference in the relationship of VFA and
vitamin D insufficiency and deficiency between post- and
pre-menopausal women in our study. On one hand, the
prevalence of vitamin D insufficiency and deficiency in our
study was higher in post-menopausal women. The vitamin
D inadequacy is also present in many postmenopausal
women in European, North American countries and
Fig. 1 Prevalence of vitamin D deficiency (25(OH) D3) <20 μg/L)
(a) or vitamin D insufficiency (25(OH) D3: 20–29 μg/L) (b) according
to the quartiles of visceral fat area in men and women. Men
(Q1: <89.95 cm2, Q2: 89.95–115.72 cm2, Q3: 115.72–140.46 cm2,
Q4: ≥140.46 cm2); Pre-menopausal women (Q1: <53.15 cm2, Q2: 53.15–
66.18 cm2, Q3: 66.18–84.47 cm2, Q4: ≥ 84.47 cm2); Post-menopausal
women (Q1: <71.55 cm2, Q2: 71.55–91.97 cm2, Q3: 91.97–115.73 cm2,
Q4: ≥115.73 cm2). *Compared with Q1, P <0.05; #Compared with Q2,
P <0.05; &Compared with Q3, P <0.05
Table 3 Characteristics of the study population according to quartiles of visceral fat area levels in women (Continued)
Doing exercise, % yes 32.20 30.51 22.03 18.97 bNS
Sunshine time, h/day 1.00(0.50–0.10) 1.00(0.00–1.00) 1.00(0.50–0.10) 1.00(0.50–0.10) bNS
Vitamin D supplement users, % yes 3.39 5.08 6.78 5.17 bNS
Values are percentages for categorical variables, means ± SDs for continuous variables with a normal distribution, or medians (95 % ranges) for continuous
variables with a skewed distribution
Abbreviations: 25(OH) D3, 25-hydroxyvitamin D3
aComparison among four groups
bNS = no significant at p value > .05
#Compared with Q1, P < 0.05
&Compared with Q2, P < 0.05
$Compared with Q3, P < 0.05
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Fig. 2 The correlation between serum 25(OH) D3 and fatness indices in men (a-e) and women [pre-menopausal women (f-j); post-menopausal women
(k-o)]. Abbreviations: 25(OH)D3, 25-hydroxyvitamin D3; BMI, body mass index; WC, waist circumference; WHR, waist-to-hip ratio; PBF, percentage body
fat; VFA, visceral fat area
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Table 4 The odd ratios of different fatness indices and vitamin D insufficiency and deficiency in men and women
Gender Fatness indices Crude model Adjusted modela
OR (95 % CI) P-Value OR (95 % CI) P-Value
Men Visceral fat area
Q1(<89.95 cm2) 1.0 1.0
Q2(89.95–115.72 cm2) 2.059(0.990–4.281) 0.053 1.320(0.476–3.662) 0.594
Q3(115.72–140.46 cm2) 3.987(1.900–8.364) 0.000 2.424(0.916–6.417) 0.075
Q4(≥140.46 cm2) 7.667(3.495–16.817) 0.000 4.894(1.792–13.365) 0.002
Continuous 1.025(1.016–1.034) 1.719(1.251–2.361)
P-value for trend 0.000 0.001
Body mass index
<28 kg/m2 1.0 1.0
≥28 kg/m2 3.930(2.162–7.142) 0.000 2.857(1.360–6.001) 0.006
Waist circumference
<90 cm 1.0 1.0
≥90 cm 3.007(1.809–4.998) 0.000 2.199(1.130–4.279) 0.020
Waist-to-hip ratio
<0.90 1.0 1.0
≥0.90 3.802(2.210–6.539) 0.000 2.052(1.010–4.169) 0.047
Pre-menopausal women Visceral fat area
Q1(<53.15 cm2) 1.0 1.0
Q2(53.15–66.18 cm2) 1.240(0.781–1.968) 0.361 1.097(0.644–1.868) 0.735
Q3(66.18–84.47 cm2) 1.257(0.803–1.068) 0.317 1.215(0.717–2.059) 0.469
Q4(≥84.47 cm2) 2.338(1.478–3.697) 0.000 1.837(1.051–3.210) 0.033
Continuous 1.013(1.008–1.018) 1.265(1.037–1.543)
P-value for trend 0.000 0.030
Body mass index
<28 kg/m2 1.0 1.0
≥28 kg/m2 3.921(1.952–7.875) 0.000 3.052(1.430–6.514) 0.004
Waist circumference
<80 cm 1.0 1.0
≥80 cm 1.809(1.297–2.523) 0.000 1.647(1.121–2.419) 0.011
Waist-to-hip ratio
<0.85 1.0 1.0
≥0.85 1.487 (1.081–2.046) 0.015 1.281(0.878–1.871) 0.199
Post-menopausal women Visceral fat area
Q1(<71.55 cm2) 1.0 1.0
Q2(71.55–91.97 cm2) 0.813(0.392–1.686) 0.577 0.912 (0.359–2.319) 0.847
Q3(91.97–115.73 cm2) 1.153(0.550–2.418) 0.706 1.254(0.506–3.106) 0.625
Q4(≥115.73 cm2) 1.800(0.829–3.909) 0.137 2.326(0.903–5.991) 0.080
Continuous 1.010(1.001–1.019) 1.012(1.002–1.022)
P-value for trend 0.028 0.024
Body mass index
<28 kg/m2 1.0 1.0
≥28 kg/m2 1.577(0.691–3.598) 0.279 1.379(0.548–3.470) 0.494
Waist circumference
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Eastern Asia [39–42]. On the other hand, there was no dif-
ference in the vitamin D insufficiency and deficiency across
the quartiles of VFA among post-menopausal women.
Thus, we did not observe a relationship between VFA and
vitamin D insufficiency and deficiency in post-menopausal
women.
Still other studies have implicated the decreased
level of serum 25(OH) D3 was considered as a risk
factor for obesity and its related metabolic disorders
including hypertension, high pulse pressure, obesity,
hyperlipidemia, diabetes, etc., which increases the
chance of cardiovascular disease [43–48]. Currently,
researches on vitamin D and metabolic syndrome or
its components, which are known to increase cardio-
vascular disease, are being conducted all over the
world [49–52]. Compared with the non-metabolic
syndrome group, serum 25(OH) D3 levels were sig-
nificantly lower in the metabolic syndrome group
[52]. Lu et al. [50] have reported that reduced serum
25(OH) D3 levels were associated with metabolic syn-
drome and its components, and in particular, obesity
was highly associated with insulin resistance and
serum 25(OH) D3 when compared to normal weight.
Among Korean studies, metabolic syndrome and
hypertension were associated with serum 25(OH) D3
levels in a study of middle-aged Koreans [51]. In fact,
Forouhi et al. reported a significant interaction
between 25(OH) D and BMI on the risk for a 10-year
increase in HOMA-IR [52]. Moreover, the release of
free fatty acids from adipose tissue can induce insulin
resistance, whereas 1, 25-hydroxyvitamin D has been
shown to counteract the free fatty acid-induced insu-
lin resistance [53]. The stronger association of vita-
min D with insulin resistance among the participants
with visceral fat obesity suggests that adequate vita-
min D status is more important for the prevention of
insulin resistance and metabolic syndrome in these
individuals. In addition, a larger VFA was strongly re-
lated to a higher prevalence of impaired fasting glu-
cose levels [54], diabetes [54], insulin resistance [54],
hypertension [55], abnormality of lipid metabolism
[56], and metabolic risk factors [56, 57]. In our study,
the prevalence of hyperglycemia and hypertriglyc-
eridemia increased with the quartiles of VFA in both
genders (Appendix Table 1), and VFA was closely
related with the indices of metabolic disorders (Appendix
Table 2). The individuals with the higher VFA levels
have the higher risk of hyperglycemia and hypertri-
glyceridemia in both genders (Appendix Table 3). In
accordance with our finding, one study has demon-
strated that the VFA rather than the WC itself was a
major determinant of metabolic syndrome in pre-
menopausal Korean women [58], whereas the WC
and VFA were similarly useful in identifying meta-
bolic syndrome in elderly Korean women [59]. Our
study highlights VFA might also be a simple and
sensitive index in routine use for screening vitamin
D deficiency and vitamin D related disease among
general.
This study has several limitations. First, the cross-
sectional study design precluded the ability to deter-
mine a causal relationship between VFA and vitamin
D insufficiency and deficiency. Second, the DEXA,
CT and MRI were not used to measure visceral fat
mass for our study because the participants in our
study from the routine health check-up. The DEXA,
CT and MRI were not the regular item of health
check-up since they require expensive and special-
ized equipment, and exposure to radiation. Third,
the intact parathyroid hormone (iPTH) is also ex-
pected to be a relevant confounder or even the
causal factor of the association between VFA and
25(OH) D3, and our study often concentrated exclu-
sively on 25(OH) D3 or iPTH without considering
the interaction between both. In addition, meno-
pausal status was based on self-reporting. Therefore,
further cohort study will be conducted to observe
the causal relations between VFA and vitamin D in-
sufficiency and deficiency.
Conclusion
In conclusion, results of our study revealed that higher
VFA increases the risk of vitamin D insufficiency and
deficiency in men and pre-menopausal women, but not
in post-menopausal women. VFA is a better and con-
venience surrogate marker for visceral adipose measure-
ment and could be used in identifying the risk of
vitamin D insufficiency and deficiency in routine health
examination.
Table 4 The odd ratios of different fatness indices and vitamin D insufficiency and deficiency in men and women (Continued)
<80 cm 1.0 1.0
≥80 cm 1.391(0.814–2.377) 0.228 1.522(0.780–2.969) 0.218
Waist-to-hip ratio
<0.85 1.0 1.0
≥0.85 1.413(0.776–2.573) 0.258 1.540(0.732–3.241) 0.255
aAdjusted for age, smoking status, drinking status, exercise status, sunshine time and lipid profiles
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Appendix Table 1
Table 5 Prevalence of components of metabolic syndrome according to quartiles of visceral fat area
Men
Quartiles of visceral fat area (cm2) P-valuea
Q1(<89.95) Q2(89.95-115.72) Q3(115.72-140.46) Q4(≥140.46)
n 64 65 64 64
Hyperglycemia 5(7.81) 20(30.77)# 17(26.56)# 19(29.69)# 0.006
Hypertriglyceridemia 12(18.75) 21(32.31) 28(43.75)# 31(48.44)# 0.002
Low HDL-C 14(21.88) 19(29.23) 23(35.94) 19(29.69) bNS
High blood pressure 12(18.75) 16(24.62) 16(25.00) 19(29.68) bNS
Pre-menopausal women
Quartiles of visceral fat area (cm2) P-valuea
Q1(<53.15) Q2(53.15–66.18) Q3(66.18–84.47) Q4(≥84.47)
n 153 144 163 153
Hyperglycemia 2(1.31) 8(5.56) 16(9.82)# 38(24.84)#&$ 0.000
Hypertriglyceridemia 2(1.31) 8(5.56) 19(11.66)# 29(18.95)#& 0.000
Low HDL-C 41(26.80) 54(37.50) 76(46.63)# 93(60.78)#&$ 0.000
High blood pressure 2(1.31) 4(2.77) 11(6.75)# 21 (13.73)#&$ 0.000
Post-menopausal women
Quartiles of visceral fat area (cm2) P-valuea
Q1(<71.55) Q2(71.55–91.97) Q3(91.97–115.73) Q4(≥115.73)
n 59 59 59 58
Hyperglycemia 12(20.34) 22(37.29) 26(44.07)# 22(37.93)# 0.045
Hypertriglyceridemia 7(11.86) 10(16.95) 20(33.90)# 24(41.38)#& 0.001
Low HDL–C 13(22.03) 20(33.90) 28(47.46)# 26(44.83)# 0.017
High blood pressure 12(18.64) 17(28.81) 15(25.42) 19(32.76) bNS
The metabolic risk factors were defined as follows: (1) high blood pressure, with systolic blood pressure of at least 130 mmHg or diastolic blood pressure of at
least 85 mmHg or taking medication for previously diagnosed hypertension; (2) hypertriglyceridemia, with TG levels of at least 150 mg/dL (1.69 mmol/L); (3) low
HDL-C, with HDL cholesterol level less than 40 mg/dL (1.03 mmol/L) for men and less than 50 mg/dL (1.29 mmol/L) for women; (4) hyperglycemia, with fasting
plasma glucose of at least 110 mg/dL (6.1 mmol/L) or taking medication for previously diagnosed type 2 diabetes
Values are number (percentages)
aComparison among four groups
bNS = no significant at p value > .05
#Compared with Q1, P < 0.05
&Compared with Q2, P < 0.05
$Compared with Q3, P < 0.05
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Appendix Table 2
Appendix Table 3
Table 6 Correlation coefficients of the relationships between visceral fat area and various parameters of metabolic risk factors
Indices Men Pre-menopausal women Post-menopausal women
r P-value r P-value r P-value
Body mass index 0.763 0.000 0.719 0.000 0.818 0.000
Waist circumference 0.818 0.000 0.949 0.000 0.879 0.000
Waist-to- hip ratio 0.899 0.000 0.893 0.000 0.930 0.000
Systolic blood pressure 0.112 0.152 0.283 0.000 0.221 0.007
Diastolic blood pressure 0.162 0.038 0.296 0.000 0.236 0.004
Total cholesterol 0.211 0.007 0.218 0.000 −0.013 0.842
Triglycerides 0.140 0.025 0.382 0.000 0.262 0.000
High-density lipoprotein cholesterol −0.198 0.011 −0.240 0.000 −0.254 0.000
Low-density lipoprotein cholesterol 0.326 0.000 0.297 0.000 0.004 0.957
Fasting plasma glucose 0.128 0.040 0.259 0.000 0.105 0.107
Table 7 Multivariate analysis of the ORs and 95 % CIs between visceral fat area and components of metabolic syndrome
Quartiles of visceral fat area
Q1 Q2 Q3 Q4
Men
Hyperglycemia 1.0 6.735(1.642–27.768) 3.996(0.940–16.979) 4.474(1.066–18.780)
Hypertriglyceridemia 1.0 1.815(0.713–4.621) 3.229(1.268–8.222) 3.418(1.358–8.602)
Low HDL-C 1.0 1.935(0.715–5.237) 2.383(0.871–6.519) 1.935(0.703–5.327)
High blood pressure 1.0 4.205(0.808–21.833) 3.707(0.715–19.203) 4.796(0.916–25.104)
Pre-menopausal women
Hyperglycemia 1.0 3.179(0.634–15.944) 3.920(0.824–18.659) 10.578(2.337–47.874)
Hypertriglyceridemia 1.0 4.441(0.927–21.277) 9.962(2.280–43.535) 17.657(4.132–75.460)
Low HDL-C 1.0 1.481(0.852–2.576) 2.103(1.219–3.628) 3.846(2.146–6.892)
High blood pressure 1.0 1.539(0.131–18.020) 1.415(0.116–17.228) 5.241(0.556–49.437)
Post-menopausal women
Hyperglycemia 1.0 3.396(1.104–10.447) 4.205(1.408–12.560) 3.867(1.304–11.466)
Hypertriglyceridemia 1.0 2.456(0.626–9.636) 4.602(1.265–16.735) 8.402(2.402–29.391)
Low HDL-C 1.0 2.293(0.860–6.110) 1.944(0.749–5.047) 1.751(0.680–4.509)
High blood pressure 1.0 1.502(0.326–6.919) 1.489(0.354–6.257) 1.607(0.408–6.330)
Odds ratios and 95 % CIs adjusted for age, smoking status, drinking status, exercise status, sunshine time. Men (Q1: <89.95 cm2, Q2: 89.95–115.72 cm2, Q3:
115.72–140.46 cm2, Q4: ≥140.46 cm2); Pre-menopausal women (Q1: <53.15 cm2, Q2: 53.15–66.18 cm2, Q3: 66.18–84.47 cm2, Q4: ≥ 84.47 cm2); Post-menopausal
women (Q1: <71.55 cm2, Q2: 71.55–91.97 cm2, Q3: 91.97–115.73 cm2, Q4: ≥115.73 cm2)
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